Thirty-one intensively pretreated children with ALL in first bone marrow relapse or refractory to initial therapy were treated with a combination of intermediate-dose Ara-C and idarubicin (IDA). Twenty-four patients (77%) achieved complete remission (CR), 8 patients relapsed early and 2 were removed from the study. Fourteen (45% of the original 31 patients) underwent bone marrow transplant (BMT) and 7 of them (22%) are still in continuous CR (CCR) with a median follow-up of 18 months. These results confirm that it is possible to achieve CR even in ALL children who failed on an initial intensive regimen. Newer modalities of post-remission therapy, especially for children lacking an HLA donor, should be considered.

Treatment of primary refractory or relapsed acute lymphoblastic leukemia (ALL) in children / Testi, Anna Maria; Moleti, Ml; Giona, F; Iori, Ap; Meloni, Giovanna; Miniero, R; Pigna, M; Amadori, S; Mandelli, Franco. - In: ANNALS OF ONCOLOGY. - ISSN 0923-7534. - 3:(1992), pp. 765-767.

Treatment of primary refractory or relapsed acute lymphoblastic leukemia (ALL) in children.

TESTI, Anna Maria;Giona F;MELONI, Giovanna;MANDELLI, Franco
1992

Abstract

Thirty-one intensively pretreated children with ALL in first bone marrow relapse or refractory to initial therapy were treated with a combination of intermediate-dose Ara-C and idarubicin (IDA). Twenty-four patients (77%) achieved complete remission (CR), 8 patients relapsed early and 2 were removed from the study. Fourteen (45% of the original 31 patients) underwent bone marrow transplant (BMT) and 7 of them (22%) are still in continuous CR (CCR) with a median follow-up of 18 months. These results confirm that it is possible to achieve CR even in ALL children who failed on an initial intensive regimen. Newer modalities of post-remission therapy, especially for children lacking an HLA donor, should be considered.
1992
01 Pubblicazione su rivista::01a Articolo in rivista
Treatment of primary refractory or relapsed acute lymphoblastic leukemia (ALL) in children / Testi, Anna Maria; Moleti, Ml; Giona, F; Iori, Ap; Meloni, Giovanna; Miniero, R; Pigna, M; Amadori, S; Mandelli, Franco. - In: ANNALS OF ONCOLOGY. - ISSN 0923-7534. - 3:(1992), pp. 765-767.
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/422806
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 8
  • ???jsp.display-item.citation.isi??? 8
social impact